DF/HCC Program Affiliation

Member, Cancer Epidemiology Program
Member, Outcomes Research Program
Member, Breast Cancer Program

Research Abstract

Dr. Winer's research focus relates to clinical research in breast cancer. In this regard, he conducts a wide variety of phase I, II, and III trials for patients with all stages of breast cancer. In addition, he has interests related to quality of life, psychosocial aspects of cancer, medical decision-making, and doctor-patient communication. Either as a principal investigator or in collaboration with others, he has conducted research in these areas.

Publications

• Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Engl J Med 2007 Jun 7; 356(23):2399-405
  PMID: 17554121
• Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology 2007 May 24;
  PMID: 17525937
• Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, W. Invasive breast cancer. J Natl Compr Canc Netw 2007 Mar; 5(3):246-312
  PMID: 17439758
• Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol 2007 Mar 20; 25(9):1074-81
  PMID: 17369571
• Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007 Mar 15; 13(6):1648-55
  PMID: 17363517
• Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007 Feb 15; 13(4):1198-207
  PMID: 17317830
• Tolaney SM, Partridge AH, Sheib RG, Burstein HJ, Winer EP. Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol 2006 Nov 20; 24(33):5330-1
  PMID: 17114668
• Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol 2006 Dec; 17(12):1777-82
  PMID: 16971671
• Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer EP. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs 2007 Apr; 25(2):161-4
  PMID: 16969707
• Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM,. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006 Jul; 4 Suppl 3:S1-22; quiz S23-4
  PMID: 16813731
• Burstein HJ, Mayer E, Patridge AH, O'Kane H, Litsas G, Come SE, Hudis CA, Goldstein DF, Muss HB, Winter EP, Garber JE. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer 2006 Jun; 7(2):158-61
  PMID: 16800976
• Hudis CA, Winer EP. Cancer and leukemia group B breast committee: decades of progress and plans for the future. Clin Cancer Res 2006 Jun 1; 12(11 Pt 2):3576s-80s
  PMID: 16740788
• Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer 2006 Jun 15; 106(12):2576-82
  PMID: 16703595
• Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006 Apr 12; 295(14):1658-67
  PMID: 16609087
• Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC,. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 2006 Mar; 4 Suppl 1:S1-26
  PMID: 16507275
• Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res 2006 Feb 1; 12(3 Pt 2):997s-1000s
  PMID: 16467115
• Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol 2006 Jan 1; 24(1):85-94
  PMID: 16382117
• Lin NU, Gelman R, Winer EP. Dose density in breast cancer: a simple message? J Natl Cancer Inst 2005 Dec 7; 97(23):1712-4
  PMID: 16333021
• Peppercorn J, Partridge A, Burstein HJ, Winer EP. Standards for follow-up care of patents with breast cancer. Breast 2005 Dec; 14(6):500-8
  PMID: 16288876
• Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys 2005 Oct 20;
  PMID: 16243442
• Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol 1999 May; 17(5):1465-73
  PMID: 10334532